Le Lézard
Classified in: Health
Subject: ATY

CHINOOK INVESTOR ALERT : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options

NEW YORK, May 27, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY).

If you suffered losses exceeding $50,000 investing in Chinook stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/KDNY.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

The investigation focuses on Chinook's statements related to the commercial prospects for its lead product candidate (atrasentan), which is under development, to treat patients with kidney disease.

As recently as April 25, 2023, Chinook assured investors that "we believe that we have developed what we think is one of the leading pipelines targeting kidney disease [...] that's really led by our -- our most advanced program, which is called atrasentan [...] that we in-licensed from AbbVie a few years ago."

But on May 16, 2023, Muddy Waters Capital published a report concluding: (1) the FDA is unlikely to approve atrasentan; (2) "atrasentan is inefficacious for chronic kidney disease"; (3) "atrasentan has been shown to be harmful to patients' cardiovascular health"; and (4) "AbbVie and Chinook seem to have systematically manipulated research findings and presentation on atrasentan to obscure these trial results."

In response, the price of Chinook shares fell sharply lower during intraday trading on May 16, 2023.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

These press releases may also interest you

30 sep 2023
A new era in the treatment of cancer with proton therapy is being ushered in by the P-Cure development of a proton system. It includes a synchrotron-based gantry-less system featuring personalized, adaptive, intensity-modulated particle therapy...

30 sep 2023
The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co.,...

30 sep 2023
The healthcare landscape in North Carolina reaches a pivotal milestone with...

30 sep 2023
Statement attributable to:Octavia Peck Palmer, PhDPresident, Association for Diagnostics & Laboratory Medicine (formerly AACC) "We at the Association for Diagnostics & Laboratory Medicine were disappointed to see the U.S. Food & Drug Administration's...

30 sep 2023
More than 1,800 Road Hockey participants and Celebrity Ambassadors came together today to take part in the 2023 Road Hockey to Conquer Cancer event, fuelled by Longo's. Thousands of passionate players and supporters from across Canada and the United...

30 sep 2023
In the heart of Canada, where the land stretches far and wide, LifeLabs is fostering a legacy of compassion and support for Indigenous communities. As we reflect and commemorate the National Day for Truth and Reconciliation, it's a moment to...

News published on and distributed by: